Parity correlates with the timing of developing endometrial cancer, but not subtype of endometrial cancer

Journal of Cancer

Volumn 6, Issue 11, 2015, Pages 1087-1092

  Chen, Qi ^a,b,c   Tong, Mancy ^b,c   Guo, Fang ^a,c   Lau, Sandy ^b,c   Zhao, Min ^a,c,d  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Endometrial cancer; Menopause; Parity; Time onset; Type I and type II

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CHINA; ENDOMETRIUM CANCER; FEMALE; HUMAN; LIVE BIRTH; MENARCHE; MENOPAUSE; NULLIPARA; PARITY; RISK FACTOR;

EID: 84949685546     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.12736     Document Type: Article

References (26)

1. Stewart BW and Wild C: World cancer report. Lyon, France. 2014.
2. Setiawan VW, Pike MC, Karageorgi S, et al: Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. Am J Epidemiol, 2012. 176(4): 269-78.
3. Nichols HB, Trentham-Dietz A, Hampton JM, Titus-Ernstoff L, Egan KM, Willett WC and Newcomb PA: From menarche to menopause: trends among US Women born from 1912 to 1969. Am J Epidemiol, 2006. 164(10): 1003-11.
4. Karageorgi S, Hankinson SE, Kraft P and De Vivo I: Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. Int J Cancer, 2010. 126(1): 208-16.
5. Kaaks R, Lukanova A, and Kurzer MS: Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev, 2002. 11(12): 1531-43.
6. Jamison PM, Noone AM, Ries LA, Lee NC, and Edwards BK: Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev, 2013. 22(2): 233-41.
7. Dossus L., Allen N., Kaaks R., et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer, 2010. 127(2): 442-51.
8. Cook LS, et al. Endometrial cancer: Cancer epidemiology and prevention. New York: Oxford University Press. 2006.
9. Miller A.B., Barclay T.H., Choi N.W., Grace M.G., Wall C., Plante M., Howe G.R., Cinader B., and Davis F.G. A study of cancer, parity and age at first pregnancy. J Chronic Dis, 1980. 33(10): 595-605.
10. Cook L.S., Kmet L.M., Magliocco A.M., and Weiss N.S. Endometrial cancer survival among U.S. black and white women by birth cohort. Epidemiology, 2006. 17(4): 469-72.
11. Schonfeld S.J., Hartge P., Pfeiffer R.M., et al. An aggregated analysis of hormonal factors and endometrial cancer risk by parity. Cancer, 2013. 119(7): 1393-401.
12. Hoffman B., Schorge J., Schaffer J., et al. Gynecology: Endometrial Cancer 2nd ed. McGraw-Hill. 2012.
13. Schorge J.O. and Williams J.W. Gynecology. New York: McGraw-Hill Medical. 2012.
14. Olson S.H., Atoria C.L., Cote M.L., Cook L.S., Rastogi R., Soslow R.A., Brown C.L., and Elkin E.B. The impact of race and comorbidity on survival in endometrial cancer. Cancer Epidemiol Biomarkers Prev, 2012. 21(5): 753-60.
15. Mahdi H., Schlick C.J., Kowk L.L., Moslemi-Kebria M., and Michener C. Endometrial cancer in Asian and American Indian/Alaskan Native women: tumor characteristics, treatment and outcome compared to non-Hispanic white women. Gynecol Oncol, 2014. 132(2): 443-9.
16. Akhmedkhanov A., Zeleniuch-Jacquotte A., and Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci, 2001. 943: 296-315.
17. Do K.A., Treloar S.A., Pandeya N., Purdie D., Green A.C., Heath A.C., and Martin N.G. Predictive factors of age at menopause in a large Australian twin study. Hum Biol, 1998. 70(6): 1073-91.
18. Setiawan V.W., Pike M.C., Kolonel L.N., Nomura A.M., Goodman M.T., and Henderson B.E. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am J Epidemiol, 2007. 165(3): 262-70.
19. Evans T., Sany O., Pearmain P., Ganesan R., Blann A., and Sundar S. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer, 2011. 104(9): 1505-10.
20. Lentz G.M. Comprehensive gynecology. 6th ed. Philadelphia: Mosby Elsevier. 2013.
21. Kim J.J. and Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod Med, 2010. 28(1): 81-90.
22. Key T.J. and Pike M.C. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer, 1988. 57(2): 205-12.
23. Henderson B.E. and Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis, 2000. 21(3): 427-33.
24. Setiawan V.W., Yang H.P., Pike M.C., et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol, 2013. 31(20): 2607-18.
25. Vale C.L., Tierney J., Bull S.J., and Symonds P.R. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev, 2012. 8: CD003915.
26. Yang D., Haines C.J., Pan P., Zhang Q., Sun Y., Hong S., Tian F., Bai B., Peng X., Chen W., Yang X., Chen Y., Feng H., Zhao S., Lei H., Jiang Z., Ma X., and Liao W. Menopausal symptoms in mid-life women in southern China. Climacteric, 2008. 11(4): 329-36.